Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Imugene

Executive interview – Imugene

Imugene is a clinical-stage immuno-oncology company. Its lead product is HER-Vaxx, a B-cell peptide vaccine for the treatment of gastric cancer. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that overexpress the HER-2/neu receptor, such as breast cancer and gastric cancer. HER-Vaxx has successfully completed a Phase I study in breast cancer and has commenced a Phase Ib/II study in gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. Imugene has broadened its pipeline with the acquisition of arginine modulators (small molecules) to develop to preclinical proof of concept.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free